Previous 10 | Next 10 |
REHOVOT, Israel, May 18, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company focused on developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcom...
Purple Biotech press release (NASDAQ:PPBT): Q1 GAAP EPS of $0.41. Cash and cash equivalents of $23.54M For further details see: Purple Biotech GAAP EPS of $0.41
REHOVOT, Israel, May 12, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced financi...
Gainers: Veru (VERU) +196%. Hoth Therapeutics (HOTH) +126%. Altamira Therapeutics (CYTO) +54%. Iveda Solutions (IVDA) +37%. VNET Group (VNET) +30%. SailPoint Technologies Holdings (SAIL) +29%. Castor Maritime (CTRM) +25%. Datto Holding (MSP) +21%. Axcella Health (AXLA) +16%. TScan Therapeutic...
The ADRs of Purple Biotech (NASDAQ:PPBT) are trading sharply lower in the morning hours after the clinical-stage pharma company announced data from a Phase 1b study for its experimental cancer drug CM24 in combination with Opdivo. As of the data cutoff on March 08, 11 patients were studied in...
First-in-class monoclonal antibody in combination with Opdivo® (nivolumab) demonstrates strong safety and an initial efficacy profile for PDAC REHOVOT, Israel, April 11, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a cli...
Mercurity Fintech Holding (MFH) +65%. Fast Radius (FSRD) +21%. Nikola (NKLA) +18% after investor event. Femasys (FEMY) +13%. BiondVax Pharmaceuticals (BVXV) +13% on research pact to develop nanosized antibody therapies. Incannex Healthcare (IXHL) +12%. D-MARKET Elektronik&...
Purple Biotech press release (NASDAQ:PPBT): FY GAAP EPS of -$1.05. As of December 31, 2021, Purple Biotech had cash and cash equivalents and short- and long-term deposits of $47.4M, compared to $60.8M on December 31, 2020. The Company believes that its cash position will provide sufficient re...
REHOVOT, Israel, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced financ...
REHOVOT, Israel, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, is pleased to i...
News, Short Squeeze, Breakout and More Instantly...
Purple Biotech Ltd ADR (Sponsored) Level 3 Company Name:
PPBT Stock Symbol:
NASDAQ Market:
REHOVOT, Israel, July 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today announced further details on its ...
REHOVOT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today anno...
REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced ...